Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes

We evaluated the in vitro activity of manogepix against Fusarium oxysporum and Fusarium solani species complex (FOSC and FSSC, respectively) isolates per CLSI document M38 broth microdilution methods. Manogepix demonstrated activity against both FOSC (MEC [minimal effective concentration] range, ≤0.015 to 0.03 μg/ml; MIC50 range, ≤0.015 to 0.125 μg/ml) and FSSC (MEC, ≤0.015 μg/ml; MIC50, ≤0.015 to 0.25 μg/ml). ABSTRACT We evaluated the in vitro activity of manogepix against Fusarium oxysporum and Fusarium solani species complex (FOSC and FSSC, respectively) isolates per CLSI document M38 broth microdilution methods. Manogepix demonstrated activity against both FOSC (MEC [minimum effective concentration] range, ≤0.015 to 0.03 μg/ml; MIC50 range, ≤0.015 to 0.125 μg/ml) and FSSC (MEC, ≤0.015 μg/ml; MIC50, ≤0.015 to 0.25 μg/ml). Amphotericin B was also active (MIC, 0.25 to 4 μg/ml), whereas the triazoles (MIC, 1 to >16 μg/ml) and micafungin (MEC, ≥8 μg/ml) had limited activity.

[1]  Yiyou Gu,et al.  Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis , 2019, Antimicrobial Agents and Chemotherapy.

[2]  M. Castanheira,et al.  In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017 , 2019, Antimicrobial Agents and Chemotherapy.

[3]  M. Cuenca‐Estrella,et al.  In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies , 2019, The Journal of antimicrobial chemotherapy.

[4]  H. Sanchez,et al.  APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis , 2019, Antimicrobial Agents and Chemotherapy.

[5]  M. Kapoor,et al.  APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia , 2018, Antimicrobial Agents and Chemotherapy.

[6]  M. Kapoor,et al.  APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis , 2018, Antimicrobial Agents and Chemotherapy.

[7]  M. H. Lee,et al.  Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis , 2018, Antimicrobial Agents and Chemotherapy.

[8]  J. Perfect,et al.  In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus , 2018, Antimicrobial Agents and Chemotherapy.

[9]  T. Walsh,et al.  Recent Advances in the Treatment of Scedosporiosis and Fusariosis , 2018, Journal of fungi.

[10]  G. S. de Hoog,et al.  Evaluation of two novel barcodes for species recognition of opportunistic pathogens in Fusarium. , 2016, Fungal biology.

[11]  M. Nucci,et al.  Fusariosis , 2015, Seminars in Respiratory and Critical Care Medicine.

[12]  T. Patterson,et al.  The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans , 2014, Antimicrobial Agents and Chemotherapy.

[13]  E. Anaissie,et al.  Improvement in the outcome of invasive fusariosis in the last decade. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  Ronald N. Jones,et al.  Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods , 2011, Antimicrobial Agents and Chemotherapy.

[15]  Ronald N. Jones,et al.  Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. , 2011, The Journal of antimicrobial chemotherapy.

[16]  Ronald N. Jones,et al.  In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. , 2011, Diagnostic microbiology and infectious disease.

[17]  Ronald N. Jones,et al.  In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods , 2011, Antimicrobial Agents and Chemotherapy.

[18]  T. Horii,et al.  In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds , 2011, Antimicrobial Agents and Chemotherapy.

[19]  T. Horii,et al.  Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis , 2011, Antimicrobial Agents and Chemotherapy.

[20]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[21]  D. Geiser,et al.  Phylogenetic Diversity and Microsphere Array-Based Genotyping of Human Pathogenic Fusaria, Including Isolates from the Multistate Contact Lens-Associated U.S. Keratitis Outbreaks of 2005 and 2006 , 2007, Journal of Clinical Microbiology.

[22]  E. Anaissie,et al.  Fusarium infection in hematopoietic stem cell transplant recipients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.